(Q35688185)

9 August 2017

1 reference

title

Sibutramine and the management of obesity (English)

1 reference

9 August 2017

0 references

1 reference

Walker S Carlos Poston

series ordinal

1

1 reference

PubMed ID

15013931

9 August 2017

John P Foreyt

series ordinal

2

1 reference

PubMed ID

15013931

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Pharmacotherapy

9 August 2017

1 reference

9 August 2017

5

1 reference

9 August 2017

3

1 reference

9 August 2017

633-642

1 reference

Economic costs of obesity and inactivity

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

The discovery and status of sibutramine as an anti-obesity drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

National trends in antiobesity medication use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Influence of sibutramine on energy expenditure in African American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Effects of Sibutramine on Binge Eating, Hunger, and Fullness in a Laboratory Human Feeding Paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

Abuse liability assessment of sibutramine, a novel weight control agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.3.633

21 January 2018

Identifiers

DOI

10.1517/14656566.5.3.633

1 reference

9 August 2017

1 reference

PubMed ID

15013931